|
|
|
|
Laboratoire de Chimie Organique Biologique, URA CNRS 493, Université Pierre et Marie Curie, 75252 Paris Cedex 05, France
(S.S., G.C., S.L.), and
Chaire de Neuropharmacologie, Institut National
de la Santé et de la Recherche Médicale U114, Collège
de France, 75005 Paris, France (J.-C.B., Y.T., M.S., J.G.)
Propionyl-[Met(O2)11]substance P(7-11)
[ALIE-124 or
propionyl-[Met(O2)11]SP(7-11)] has been
designed as a septide-like ligand adequate for tritiation and,
therefore, adequate for binding studies. In Chinese hamster ovary (CHO)
cells expressing human tachykinin neurokinin (NK)-1 receptors, ALIE-124
displaced [3H][Pro9]substance P (SP) from
its binding site at micromolar concentrations. However, ALIE-124
stimulated phosphatidylinositol hydrolysis, as previously shown for
septide-like peptides. With [3H]ALIE-124 (95 Ci/mmol), we
have been able to reveal a high affinity binding site in CHO cells
(Kd = 6.6 ± 1.0 nM), with
a low maximal binding capacity. [3H]ALIE-124 specific
maximal binding represented only 15-20% of that observed with
[3H][Pro9]SP in CHO cells. Septide-like
peptides, including septide and NKA, were potent competitors (in
the nanomolar range) of [3H]ALIE-124 specific binding
site. Interestingly, SP and [Pro9]SP were also
potent competitors, with 10-fold greater potency for sites labeled
with [3H]ALIE-124 than for sites labeled with
[3H][Pro9]SP. The NK-1 antagonist RP 67580 also showed a higher potency for [3H]ALIE-124 than for
[3H][Pro9]SP-specific binding sites. NKB
and
[Lys5,methyl-Leu9,Nle10]NKA(4-10)
displaced [3H]ALIE-124 binding but with lower potency,
whereas senktide had no affinity. The existence of
[3H]ALIE-124 specific binding sites was also demonstrated
in rat submandibular gland. In this tissue, [3H]ALIE-124
specific maximal binding was higher, reaching 40-50% of that achieved
with [3H][Pro9]SP.
This article has been cited by other articles:
![]() |
M. M. Rosenkilde, R. David, I. Oerlecke, T. Benned-Jensen, U. Geumann, A. G. Beck-Sickinger, and T. W. Schwartz Conformational Constraining of Inactive and Active States of a Seven Transmembrane Receptor by Metal Ion Site Engineering in the Extracellular End of Transmembrane Segment V Mol. Pharmacol., December 1, 2006; 70(6): 1892 - 1901. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Simmons Functional Selectivity of NK1 Receptor Signaling: Peptide Agonists Can Preferentially Produce Receptor Activation or Desensitization J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 907 - 913. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Shafer, V. J. Bennett, P. Kim, and J. C. Voss Probing the Binding Pocket and Endocytosis of a G Protein-coupled Receptor in Live Cells Reported by a Spin-labeled Substance P Agonist J. Biol. Chem., September 5, 2003; 278(36): 34203 - 34210. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Martini, H. Hastrup, B. Holst, A. Fraile-Ramos, M. Marsh, and T. W. Schwartz NK1 Receptor Fused to beta -Arrestin Displays a Single-Component, High-Affinity Molecular Phenotype Mol. Pharmacol., July 1, 2002; 62(1): 30 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Lequin, G. Bolbach, F. Frank, O. Convert, S. Girault-Lagrange, G. Chassaing, S. Lavielle, and S. Sagan Involvement of the Second Extracellular Loop (E2) of the Neurokinin-1 Receptor in the Binding of Substance P. PHOTOAFFINITY LABELING AND MODELING STUDIES J. Biol. Chem., June 14, 2002; 277(25): 22386 - 22394. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Pineyro, M. Azzi, A. De Lean, P. Schiller, and M. Bouvier Short-Term Inverse-Agonist Treatment Induces Reciprocal Changes in delta -Opioid Agonist and Inverse-Agonist Binding Capacity Mol. Pharmacol., October 1, 2001; 60(4): 816 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Rosenkilde and T. W. Schwartz Potency of Ligands Correlates with Affinity Measured against Agonist and Inverse Agonists but Not against Neutral Ligand in Constitutively Active Chemokine Receptor Mol. Pharmacol., March 1, 2000; 57(3): 602 - 609. [Abstract] [Full Text] |
||||
![]() |
S. Sagan, P. Karoyan, G. Chassaing, and S. Lavielle Further Delineation of the Two Binding Sites (R*n) Associated with Tachykinin Neurokinin-1 Receptors Using [3-Prolinomethionine11]SP Analogues J. Biol. Chem., August 20, 1999; 274(34): 23770 - 23776. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Rosenkilde, T. N. Kledal, H. Brauner-Osborne, and T. W. Schwartz Agonists and Inverse Agonists for the Herpesvirus 8-encoded Constitutively Active Seven-transmembrane Oncogene Product, ORF-74 J. Biol. Chem., January 8, 1999; 274(2): 956 - 961. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pellegrini, A. A. Bremer, A. L. Ulfers, N. D. Boyd, and D. F. Mierke Molecular Characterization of the Substance P{middle dot}Neurokinin-1 Receptor Complex. DEVELOPMENT OF AN EXPERIMENTALLY BASED MODEL J. Biol. Chem., June 15, 2001; 276(25): 22862 - 22867. [Abstract] [Full Text] [PDF] |
||||